Literature DB >> 9815130

Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass.

T H Kwon1, J Frøkiaer, M A Knepper, S Nielsen.   

Abstract

Urinary concentration characteristically decreases in response to a reduction in renal mass in chronic renal failure (CRF). In the present study, we examined whether there are changes in the expression of aquaporins in rats where CRF was induced by 5/6 nephrectomy. Plasma creatinine levels were significantly elevated consistent with significant CRF: 135.7 +/- 15.1 (n = 17, CRF) vs. 33. 9 +/- 1.1 micromol/l (n = 11, sham), P < 0.05. Two weeks after 5/6 nephrectomy, the remnant kidneys were hypertrophied, and total renal mass increased to 65 +/- 3% of sham levels (P < 0.05). Urine production increased markedly from 40 +/- 2 to 111 +/- 3 microliter. min-1. kg-1 in CRF rats (P < 0.05), whereas urine osmolality and solute-free water reabsorption decreased significantly. Quantitative immunoblotting of total kidney membrane fractions revealed a significant decrease in total kidney AQP2 expression in CRF rats to 43 +/- 12% of sham levels (P < 0.05). A similar reduction was observed for AQP1 and AQP3. Furthermore, the increased urine output and decreased urine osmolality persisted in CRF rats despite 7 days treatment with 1-desamino-[8-D-arginine]vasopressin (DDAVP, 0.1 microgram/h sc) compared with untreated sham-operated controls. Also, there was no change in AQP2 expression (which remained at 38 +/- 3% of sham levels, P < 0.05), urine output, or urine osmolality between CRF rats with or without DDAVP treatment. Immunocytochemistry confirmed the decreased AQP2 expression in collecting duct principal cells in CRF rats, with a predominant apical labeling. In conclusion, the results demonstrated that there was a significant vasopressin-resistant downregulation of AQP2 and AQP3 as well as downregulation of AQP1 associated with the polyuria in CRF rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815130     DOI: 10.1152/ajprenal.1998.275.5.F724

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  25 in total

1.  Tissue, urine and blood metabolite signatures of chronic kidney disease in the 5/6 nephrectomy rat model.

Authors:  Munsoor A Hanifa; Martin Skott; Raluca G Maltesen; Bodil S Rasmussen; Søren Nielsen; Jørgen Frøkiær; Troels Ring; Reinhard Wimmer
Journal:  Metabolomics       Date:  2019-08-17       Impact factor: 4.290

2.  Adaptive changes in GFR, tubular morphology, and transport in subtotal nephrectomized kidneys: modeling and analysis.

Authors:  Anita T Layton; Aurélie Edwards; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-22

3.  GATA2 regulates body water homeostasis through maintaining aquaporin 2 expression in renal collecting ducts.

Authors:  Lei Yu; Takashi Moriguchi; Tomokazu Souma; Jun Takai; Hironori Satoh; Naoki Morito; James Douglas Engel; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2014-03-17       Impact factor: 4.272

4.  Cardiac function and tolerance to ischemia-reperfusion injury in chronic kidney disease.

Authors:  James M Kuczmarski; Christopher R Martens; Shannon L Lennon-Edwards; David G Edwards
Journal:  Nephrol Dial Transplant       Date:  2013-10-22       Impact factor: 5.992

5.  Effect of Micardis on the expression of renal medulla aquaporin-2 in diabetic mice.

Authors:  Lijun Yao; Jianqing Wang; Anguo Deng; Jianshe Liu; Hong Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

6.  Angiotensin II AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.

Authors:  Eun-Jung Kim; Yong-Wuk Jung; Tae-Hwan Kwon
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

7.  Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats.

Authors:  Kumiko Nishihara; Satohiro Masuda; Shunsaku Nakagawa; Atsushi Yonezawa; Takaharu Ichimura; Joseph V Bonventre; Ken-ichi Inui
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-13

Review 8.  Dysnatremias in patients with kidney disease.

Authors:  Sara Combs; Tomas Berl
Journal:  Am J Kidney Dis       Date:  2013-11-14       Impact factor: 8.860

9.  Vasopressin in chronic kidney disease: an elephant in the room?

Authors:  Vicente E Torres
Journal:  Kidney Int       Date:  2009-11       Impact factor: 10.612

Review 10.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.

Authors:  Hanne B Moeller; Søren Rittig; Robert A Fenton
Journal:  Endocr Rev       Date:  2013-01-29       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.